We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current CREO market cap is 54.14M. The company's latest EPS is GBP -0.0526 and P/E is -2.49.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Revenue | 13k | 9.43M | 25.16M | 27.17M | 30.8M |
| Operating Income | -18.89M | -23.48M | -29.91M | -30.76M | -24.8M |
| Net Income | -15.91M | -20.32M | -24.6M | -26.94M | -21.7M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Assets | 88.26M | 92.46M | 100.61M | 75.34M | 76.6M |
| Total Liabilities | 5.6M | 29.66M | 27.29M | 25.93M | 16.8M |
| Total Equity | 82.66M | 62.81M | 73.32M | 49.4M | 59.8M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Operating | -11.85M | -16.28M | -26.01M | -25.05M | -21.6M |
| Investing | -807k | -20.97M | -7.84M | -5.96M | -18.3M |
| Financing | 49.12M | 1.33M | 31.99M | 522k | 29.8M |
| Market Cap | 54.14M |
| Price to Earnings Ratio | -2.49 |
| Price to Sales Ratio | 1.76 |
| Price to Cash Ratio | 17.97 |
| Price to Book Ratio | 0.9 |
| Dividend Yield | - |
| Shares Outstanding | 412.47M |
| Average Volume (1 week) | 510.64k |
| Average Volume (1 Month) | 897.23k |
| 52 Week Change | -63.79% |
| 52 Week High | 40.25 |
| 52 Week Low | 12.625 |
| Spread (Intraday) | 0.25 (1.89%) |
| Company Name | Creo Medical Group Plc |
| Address |
block b south wales NP16 5TY |
| Website | https://www.creomedical.com |
| Industry | surgical,med instr,apparatus (3841) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
